Conference Proceedings

Additional courses of alemtuzumab improved clinical and MRI outcomes in pooled CARE-MS I and II patients with disease activity after three courses: analysis of patients who received >= 4 courses

S Schippling, AD Bass, A Boster, R Berkovich, G Comi, O Fernandez, HJ Kim, V Limmroth, J Lycke, RAL Macdonell, BA Singer, P Vermersch, H Wiendl, T Ziemssen, L Chung, N Daizadeh, CE Rodriguez, A Traboulsee


University of Melbourne Researchers


Funding Acknowledgements

SS: Consulting and/or speaking fees (Biogen, Merck Serono, Novartis, Sanofi, and Teva); grant/research support (Novartis and Sanofi). ADB: Consulting fees/fees for non-CME services from commercial interest or their agents/grant and research support (Biogen, Mallinckrodt, Novartis, Roche-Genentech, Sanofi, Teva Neuroscience, and TG Therapeutics). AB: Consulting fees and/or fees for non-CME services (Biogen, Mallinckrodt, Medtronic, Novartis, Sanofi, and Teva). RB: Advisory boards and consulting (Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva). GC: Consulting fees (Actelion, Bayer, Merck Serono, Novartis, Sanofi, and Teva); lecture fees (Bayer, Biogen Dompe, Merck Serono, Novartis, Sanofi, Serono Symposia International Foundation, and Teva). OF: Speaking and/or consulting (Allergan, Almirall, Bayer-Schering, Biogen, Merck Serono, Novartis, Sanofi, and Teva); compensation for serving as a journal editor, associate editor, or member of an editorial advisory board (Revista Espanola de Esclerosis Multiple); and research support (Hospital Foundation FIMABIS). HJK: Consulting and/or speaking fees (Bayer, Biogen, Celltrion, Eisai, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok, and UCB); research support (Genzyme, Merck Serono, Ministry of Science & ICT, Teva-Handok, and UCB); steering committee member (MedImmune); co-editor (Multiple Sclerosis - Journal Experimental, Translational, and Clinical); and associate editor (Journal of Clinical Neurology). VL: Honoraria for consulting and speaking at symposia (Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi, and Teva, with approval by the HR Department, Cologne General Hospital, and University of Cologne). JL: Travel support and/or lecture honoraria (Biogen, Novartis, Sanofi, and Teva); scientific advisory boards (Almirall, Biogen, Novartis, Sanofi, and Teva); unconditional research grants (Biogen, Novartis, and Teva); and editorial board (Acta Neurologica Scandinavica). RALM: Compensation for advisory board and/or speaking fees (Bayer, Biogen, Merck, Novartis, Roche, Sanofi, and Teva) and research support (Biogen, Merck, Novartis, Sanofi, and Teva). BAS: Speaking and/or consulting (Acorda, Bayer, Biogen, EMD Serono, Genentech, Novartis, Sanofi, and Teva), and research support (Acorda, Alkermes, Biogen, MedImmune, Novartis, Roche, and Sanofi). PV: Consulting and/or speaking fees, and research support (Almirall, Bayer, Biogen, Celgene, Merck Serono, Novartis, Sanofi, Servier, and Teva). HW: Consulting and/or speaking fees (Bayer, Biogen, Behring, EMD Serono, Fresenius Medical Care, Merck Serono, Novartis, Roche, Sanofi, and Teva); license fee payments (Huber-Verlag); and grant/research support (Neotope Bioscience, Novartis, and PML Consortium). TZ: Consulting and/or speaking fees (Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi, and Teva) and grant/research support (Biogen, Novartis, Sanofi, and Teva). LC, ND, and CER: Employees of Sanofi. AT: Consulting and/or speaking fees and grant/research support (Biogen, Chugai, Roche, Sanofi, and Teva).STUDY SUPPORT: Sanofi and Bayer HealthCare Pharmaceuticals.